Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study.
about
Adalimumab effectiveness in Behçet's disease: short and long-term data from a multicenter retrospective observational study.A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study.Certolizumab Pegol treatment in Behcet's disease with different organ involvement: A multicenter retrospective observational study.New therapeutic solutions for Behçet's syndrome.Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis.Long-term efficacy and safety of anakinra in a patient with Behçet's disease and concomitant tuberculosis infection.
P2860
Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Safety profile of biologic age ...... er observational cohort study.
@en
type
label
Safety profile of biologic age ...... er observational cohort study.
@en
prefLabel
Safety profile of biologic age ...... er observational cohort study.
@en
P2093
P2860
P50
P356
P1476
Safety profile of biologic age ...... ter observational cohort study
@en
P2093
Elena Silvestri
Mauro Galeazzi
Rolando Cimaz
Rosaria Talarico
Rossella Franceschini
P2860
P304
P356
10.1111/1756-185X.12732
P50
P577
2015-08-18T00:00:00Z